Added to YB: 2025-12-18
Pitch date: 2025-10-14
DCTH [neutral]
Delcath Systems, Inc.
-12.86%
current return
Author Info
No bio for this author
Company Info
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
Market Cap
$356.0M
Pitch Price
$11.43
Price Target
N/A
Dividend
N/A
EV/EBITDA
43.38
P/E
292.12
EV/Sales
3.37
Sector
Health Care Equipment and Supplies
Category
growth
Riverwater Partners Micro Opportunities Strategy Portfolio Holding: Delcath Systems, Inc.
DCTH (holding update): Commercial oncology co w/ proprietary Hepzato Kit for liver-directed cancer therapy. Q3 underperformed on Medicaid pricing pressure & slow site activations despite growing volumes. CHOPIN trial results expected Oct could expand to 1st-line use. Compelling small-cap biotech story.
Read full article (1 min)